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ABSTRACT 
CONTEXT AND OBJECTIVE: It has been estimated that 50 million people worldwide suffer from epilepsy and around 30% will not achieve adequate control 
over the disease. The aim was to evaluate the effectiveness of oxcarbazepine for refractory partial or generalized epilepsy. 
METHODS: Systematic review. A search was conducted in the PubMed, Lilacs, EMBASE and CENTRAL databases. Studies were analyzed using the 
Cochrane Collaboration methodology.
RESULTS: Four randomized clinical trials of medium to poor methodological quality were included. Among the adult patients, the chances that they would 
obtain a 50% reduction in seizure frequency were greater after using oxcarbazepine at doses of 600 mg (relative risk, RR 2.11; 95% confidence interval, 
CI 1.32 to 3.35), 1,200 mg (RR 3.24; 95% CI 2.11 to 4.98) and 2,400 mg (RR 3.83; 95% CI 2.59 to 5.97). Among the children, the response in the 
group using oxcarbazepine was also greater (RR 2.11; 95% CI 1.32 to 3.35). The oxcarbazepine doses of 1,200 mg (RR 17.59; 95% CI 2.37 to 130.35) 
and 2,400 mg (RR 25.41; 95% CI 6.26 to 103.10) were effective for keeping patients probably free from seizures, but the dose of 600 mg was not. There 
was no significant difference between oxcarbazepine and carbamazepine for controlling the crises.  
CONCLUSIONS: There is moderate evidence indicating that oxcarbazepine is effective as an alternative treatment for partial or generalized epilepsy in 
children and adults who were refractory to previous treatment. 
RESUMO
CONTEXTO E OBJETIVO: Estima-se que 50 milhões de pessoas no mundo sofrem de epilepsia e cerca de 30% não obterão controle adequado da doença. 
O objetivo foi de avaliar a efetividade de oxcarbazepina na epilepsia parcial ou generalizada refratária.
MÉTODOS: Revisão sistemática. A busca foi nas bases de dados PubMed, Lilacs, EMBASE e CENTRAL. Os estudos foram analisados segundo a 
metodologia da Cochrane Colaboration. 
RESULTADOS: Foram incluídos quatro ensaios clínicos aleatórios de média a má qualidade. Entre os pacientes adultos as chances de obterem redução 
de 50% na frequência de convulsões foram maiores após uso de oxcarbazepina na dose de 600 mg (risco relativo, RR 2.11; intervalo de confiança, IC 
95% 1,32 a 3,35; na dose de 1.200 mg (RR 3,24; IC 95% 2,11 a 4,98) e na dose de 2.400 mg (RR 3,83; IC 95% 2,59 a 5,97). Entre as crianças a 
resposta no grupo usando oxcarbazepina também foi significativamente maior (RR 2,11; IC 95% 1,32 a 3,35). Oxcarbazepina mostrou probabilidade 
dos pacientes ficarem livre de convulsões, ser eficaz nas doses de 1.200 mg (RR 17,59; IC 95% 2.37 a 130,35) e 2.400 mg (RR 25,41; IC 95% 6,26 a 
103,10) não foi eficaz na dose de 600 mg. Não houve diferença estatística significante entre oxcarbazepina e carbamazepina no controle das crises.
CONCLUSÕES: Há evidências moderada de que a oxcarbazepina é um tratamento eficaz como alternativa para os casos de epilepsia parcial ou 
generalizada em crianças e adultos que tenham sido refratários a tratamento prévio. 
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INTRODUCTION
Epilepsy is a disease characterized by a wide range of symptoms re-
sulting from a variety of cerebral disorders. Semiologically, it is classified 
as partial or generalized. The clinical manifestations can arise through 
sensitive, sensory, psychological, vegetative and motor signs and symp-
toms of simple or complex nature, depending on the neural system im-
plicated in the genesis of the disease. Epilepsy crises have a recurrent na-
ture and tend to always present with the same characteristics over long 
periods. Epilepsy is not a single disease but represents a variety of diseas-
es with underlying cerebral dysfunctions that may have different causes. 
Thus, a priori, it comprises a heterogenous clinical entity.1
It has been estimated that 50 million people worldwide suffer 
from epilepsy. Partial epilepsy is the most common form, occurring in 
around 60% of epilepsy patients. Up to 30% of epilepsy patients will 
not achieve adequate control over the disease.2
It is important to differentiate convulsions from epileptic seizures. 
Convulsions signify transitory occurrences of signs and symptoms re-
sulting from synchronic or excessively abnormal neuronal activity in the 
brain, triggered by convulsogenic factors. These include metabolic dis-
orders involving glucose, electrolytes, increased temperature or cranial-
encephalic trauma, among others. On the other hand, epilepsy is a ce-
rebral disorder with long-lasting predisposition towards generating epi-
leptic crises, which lead to neurobiological, cognitive, psychological and 
social consequences. Status epilepticus is a severe form of clinical pre-
sentation of epileptic crises and is characterized by long duration. De-
pending on the type of crisis, it may have high morbidity-mortality.1 
Antiepileptic drugs are the initial treatment for the great majority 
of epilepsy patients. For 150 years, physicians have been prescribing an-
tiepileptic drugs to patients with recent diagnoses of epilepsy, without 
any formal scientific evaluation regarding the efficacy, safety and toler-
ability of such drugs. For example, phenobarbital and phenytoin were 
registered and put on the market without any randomized clinical tri-
al having been conducted to evaluate their efficacy and safety.3 Indica-
tion of a specific drug for a particular condition of epilepsy is based on 
clinical studies with varying levels of evidence, many without sufficient 
methodological quality. Drugs are chosen with regard not only to the 
data on the clinical trials available, but also to variables such as the type 
of epilepsy, the patient’s age and the supposed mechanism of action of 
the drug.
The action of antiepileptic drugs occurs through several mecha-
nisms. In the case of oxcarbazepine (a carbamazepine derivative), the 
action is through selective blockade of sodium channels. Oxcarbazepine 
is almost completely absorbed after a single oral dose and is rapidly me-
tabolized to the active monohydroxy form, which is the major pharma-
cologically active component of this substance.4,5
Oxcarbazepine is considered effective for treating partial epilepsy in 
adults and children, both as monotherapy and in association with oth-
er antiepileptic drugs.5 When used as monotherapy, it is recommended 
that carbamazepine [oxcarbamazepine] should be started at a dose of 
600 mg per day, divided into two doses. If necessary, the dose can be in-
creased every week until achieving control over the seizures or until rea-
ching a maximum dose of 2,400 mg per day.5 
In patients with recently diagnosed epilepsy, the therapeutic re-
sponse is commonly observed at a dosage of 1,200 mg per day. In cases 
that are refractory to monotherapy, the therapeutic response is most fre-
quently achieved at a dosage of 2,400 mg per day.5 
OBJECTIVES
The objectives of the present review were: to evaluate whether ox-
carbazepine is effective and safe for treating refractory epilepsy; whether 
oxcarbazepine used as monotherapy is effective and safe for treating re-
fractory epilepsy in adults and children; and whether the use of oxcarba-
zepine as adjuvant treatment is effective and safe for treating refractory 
epilepsy in adults and children.
METHODS
Data sources and searches
A wide-ranging search was conducted in several electronic data-
bases in order to identify all the relevant randomized clinical trials that 
have evaluated the effectiveness of oxcarbazepine for treating refractory 
epilepsy.
There were no language restrictions. Studies were considered eligible 
whether published or not. 
The following sources and strategies were used in searching for studies:
Electronic databases
Cochrane Central Register of Controlled Trials (CENTRAL; Cochrane Library 
Vol. 2, 2008)
 Phase 1 - Oxcarbazepine
 Phase 2 - “Epilepsy OR Epilepsia OR Seizure” 
 Phase 3 - #1 AND #2
Medical Literature Analysis and Retrieval System Online (Medline), via 
PubMed interface (1966 – July 2008) 
 #1 (“oxcarbazepine “[Substance Name]) OR (oxcarbazepine) OR 
(GP 47680) OR (Timox) OR (Desitin brand of oxcarbazepine) OR 
(Trileptal) OR (Novartis brand of oxcarbazepine)
 #2 (“Epilepsy”[Mesh]) OR (Epilepsy) OR (Epilepsies) OR (Epi-
leptic Seizures) OR (Epileptic Seizure) OR (Seizure, Epileptic) 
OR (Seizure Disorder) OR (Seizure Disorders) OR (Seizures, 
Epileptic) OR (Single Seizure) OR (Seizure, Single) OR (Sei-
zures, Single) OR (Single Seizures) OR (Aura) OR (Auras) OR 
(Awakening Epilepsy) OR (Epilepsy, Awakening) OR (Epilep-
sy, Cryptogenic) OR (Cryptogenic Epilepsies) OR (Cryptogen-
ic Epilepsy) OR (Epilepsies, Cryptogenic) OR (REFRACTORY 
EPILEPSY)
 #3 (randomized controlled trial [pt] OR controlled clinical trial [pt] 
OR randomized controlled trials [mh] OR random allocation [mh] 
OR double-blind method [mh] OR single-blind method [mh] OR 
clinical trial [pt] OR clinical trials [mh] OR (“clinical trial” [tw]) 
OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) 
AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR pla-
cebo* [tw] OR random* [tw] OR research design [mh:noexp] OR 
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comparative study [mh] OR evaluation studies [mh] OR follow-up 
studies [mh] OR prospective studies [mh] OR control* [tw] OR 
prospectiv* [tw] OR volunteer* [tw]) NOT (animals [mh] NOT 
humans [mh])
 #4 = #1 AND #2 AND #3
Literatura Latino-Americana e do Caribe em Ciências da Saúde (Lilacs)
 (oxcarbazepine) OR (oxcarbazepine) OR (GP 47680) OR (Timox) 
OR (Desitin brand of oxcarbazepine) OR (Trileptal) OR (Novar-
tis brand of oxcarbazepine) [Palavras] and (Epilepsy) OR (Epilep-
sies) OR (Epileptic Seizures) OR (Epileptic Seizure) OR (Seizure, 
Epileptic) OR (Seizure Disorder) OR (Seizure Disorders) OR 
(Seizures, Epileptic) OR (Single Seizure) OR (Seizure, Single) OR 
(Seizures, Single) OR (Single Seizures) OR (Aura) OR (Auras) OR 
(Awakening Epilepsy) OR (Epilepsy, Awakening) OR (Epilepsy, 
Cryptogenic) OR (Cryptogenic Epilepsies) OR (Cryptogenic Ep-
ilepsy) OR (Epilepsies, Cryptogenic) OR (REFRACTORY EPI-
LEPSY) [Palavras]
Excerpta Medica Database (Embase)
 Phase 1 - Oxcarbazepine
 Phase 2 - “Epilepsy OR Epilepsia OR Seizure” 
 Phase 3 - #1 AND #2
Websites
Websites of clinical trial registers were investigated in order to find 
any possible randomized clinical trials in progress.
http://www.controlledtrials.com
http://clinicaltrials.gov/ct/gui 
Lists of references
The lists of references of the clinical trials identified and references 
in review articles were scrutinized to locate any additional studies that 
were not located through the databases. 
CRITERIA FOR STUDY INCLUSION
Types of studies
Randomized or quasi-randomized trials.
Types of participants
Patients with any type of refractory partial or generalized epilepsy 
were included. Cases in which the patients continued to present seizures 
despite using at least two antiepileptic drugs were classified as refractory 
epilepsy. Recently diagnosed epilepsy patients without previous treat-
ment were not included.
Types of intervention
The types of intervention included were oxcarbazepine versus pla-
cebo, oxcarbazepine versus other antiepileptic drugs and oxcarbazepine 
as adjuvant treatment for another antiepileptic drug versus other anti-
epileptic drugs.
Randomized clinical trials comparing different dosages of oxcarba-
zepine that did not have a control group, taking placebo or another 
drug, were not included. 
Types of outcomes
• Reduction in seizure frequency of at least 50%: proportion of pa-
tients with a reduction in seizure frequency of 50% or more over the 
treatment period, compared with the baseline pre-randomization 
period.
• Absence of convulsive crises during the follow-up period.
• Treatment dropout rate: the proportion of the patients that aban-
doned the treatment because of its lack of efficacy or because of ad-
verse events.
• Adverse events.
This study could not evaluate cognitive and quality-of-life effects, 
because no randomized clinical study evaluating these outcomes was 
identified. 
The titles and abstracts of all the articles were scrutinized. Com-
plete photocopies of all relevant studies or studies that fulfilled the 
inclusion criteria were obtained. After reading the articles, the stud-
ies that fulfilled the inclusion criteria were evaluated with regard to 
methodological quality, and all the relevant information was extracted 
from them. 
To qualitatively evaluate the methodology of the randomized clini-
cal trials, the criteria described by Schulz et al. and the criteria described 
in the Handbook of the Cochrane Collaboration were used.7 
Methodological quality was not used as an exclusion criterion. 
Data-gathering methods
A standard form was used for extracting the relevant information 
from each article that was included.
Data analysis
For dichotomous variables, relative risk and risk difference with 
95% confidence intervals were calculated by means of fixed models. For 
continuous variables, the weighted mean difference and respective con-
fidence interval were used. 
The RevMan 5 statistical package supplied by the Cochrane Col-
laboration was used to perform meta-analysis. If meta-analysis could 
not be performed, the study results were converted into relative risks 
or weight mean differences with their respective confidence inter-
vals. 
In the event of a meta-analysis with statistically significant heteroge-
neity (P < 0.1), the randomized model was adopted. For comparisons in 
which statistical significance was observed, the number needed to treat 
or number needed to harm was calculated.   
The presence of heterogeneity was investigated by means of the chi-
squared test and the I2 test. The heterogeneity was considered statisti-
cally significant when I2 was greater than 50% and the P-value was less 
than < 0.10 (< 10%). Values of I2 between 30% and 50% were taken to 
suggest notable but nonsignificant heterogeneity.7
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RESULTS
Four randomized clinical trials were identified. Three of them com-
pared oxcarbazepine with placebo and one of them compared oxcarba-
zepine with carbamazepine among patients with difficult-to-control epi-
lepsy (Tables 1 and 2).8-18
Characteristics of the studies included
The study by Schachter included patients from the age of 12 years 
upwards who had presented two to ten epileptic crises, of which at least 
one was a complex partial seizure that had not responded to treatment. 
The patients were randomly distributed to receive oxcarbazepine 2,400 
mg or placebo.19 Among the outcomes planned for the present system-
atic review, the study by Schachter included only the incidence of sei-
zure-free patients and the incidence of adverse effects. The follow-up pe-
riod for assessing the treatment efficacy was only 10 days in length.
The study by Barcs included men and women between the ages of 15 
and 65 years with simple or complex crises of partial or generalized type, 
in accordance with the classification of the International League Against 
Epilepsy (1981 and 1989), which were not adequately controlled using 
one to three antiepileptic drugs concomitantly.20 The patients randomly 
received oxcarbazepine 600 mg, or oxcarbazepine 1,200 mg, or oxcarba-
zepine 2,400 mg or placebo. The outcomes analyzed were: 50% reduction 
in seizure frequency, incidence of seizure-free patients, dropout due to ad-
verse events, incidence of adverse events and adverse events classified as 
serious. The follow-up period was only 29 days in length.20
The study by Glauser included children between the ages of three 
and seventeen years with simple or complex crises of partial or gener-
alized type, in accordance with the classification of the International 
League Against Epilepsy (1981 and 1989), which were not adequate-
ly controlled using one or two antiepileptic drugs concomitantly.21 Pa-
tients who fulfilled the inclusion criteria were randomly distributed to 
receive oxcarbazepine 30 to 46 mg/kg or placebo. The outcomes ana-
lyzed were: incidence of seizure-free patients, dropout due to adverse 
events, incidence of adverse events and adverse events classified as seri-
ous. The follow-up period was 112 days.21
The study by Reinikainen included adult epilepsy patients with an 
unsatisfactory response to phenytoin or patients who had presented un-
desirable effects with this drug. The patients were randomized to re-
ceive oxcarbazepine 200 mg, increasing gradually to 800 mg; or carbam-
azepine 300 mg, increasing to 1,200 mg. The outcomes analyzed were: 
seizure frequency, seizure-free patients and incidence of side effects. The 
follow-up period was three months.22
Evaluation of methodological quality
The four studies included could be classified as presenting poor to 
moderate quality. A brief description of the methodological characteris-
tics is given below, and the risk of bias can be seen in Figure 1.
Generation of allocation sequence
The studies by Barcs and Reinikainen20,22 did not describe the meth-
od used for generating allocations. In the studies by Schachter and Glaus-
er, a computer was used to generate the randomization sequence.19,21
Allocation concealment
The studies by Barcs and Reinikainen20,22 did not describe the meth-
od used for concealing the allocations. The study by Schachter reported 
that the code was kept closed, but the method was not described. Cen-
tral randomization was used in the study by Glauser.19,21 
Blinding
All of the studies were described as double-blind, but there was no 
information about which aspects involved were blinded. The placebo 
was described as identical in the studies by Glauser et al.21 and Schachter 
Database Citations Studies identified
PubMed 195 4
Embase 138 4
CENTRAL 129 4
Table 1. Results from searching through the literature in the databases
Study Reasons for exclusion
Christe et al. (1997)8 This was a clinical trial evaluating the effect of oxcarba-
zepine on recently diagnosed epilepsy patients, without 
previous treatment, and therefore it did not include 
refractory patients.
Guerreiro et al. (1997)9 This was a clinical trial evaluating the effect of oxcarba-
zepine on recently diagnosed epilepsy patients, without 
previous treatment, and therefore it did not include 
refractory patients.
Kutluay et al. (2003)10 This was not a randomized clinical trial.
Passarella et al. (2005)11 This was not a randomized clinical trial.
Albani et al. (2004)12 This was a randomized clinical trial comparing different 
strategies for replacing carbamazepine with oxcarba-
zepine, and there was no comparison with placebo or 
other drugs. 
Albani et al. (2007)13 This was not a randomized clinical trial.
Beydoun et al. (2000)14 This was a randomized clinical trial comparing different 
dosages of oxcarbazepine, and there was no comparison 
with placebo or other drugs.
Beydoun et al. (2003)15 This was not a randomized clinical trial.
Bill et al. (1997)16 This was a clinical trial evaluating the effect of oxcarba-
zepine on recently diagnosed epilepsy patients, without 
previous treatment, and therefore it did not include 
refractory patients.
Piña-Garza et al. (2005)17 This was a randomized clinical trial comparing different 
dosages of oxcarbazepine, and there was no comparison 
with placebo or other drugs.
Sachdeo et al. (2001)18 This was a randomized clinical trial comparing different 
dosages of oxcarbazepine, and there was no comparison 
with placebo or other drugs.
Table 2. Characteristics of the studies excluded
Adequate sequence generation?
Allocation concealment?
Blinding?
Free from selective reporting?
Free of other bias?
0%
Yes (low risk of bias) No (high risk of bias)Unclear
25% 50% 75% 100%
Figure 1. Bar chart showing the risk of bias from combining the studies 
that were included. It can be seen that there was a moderate to high risk 
of bias.
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et al.19 In the study by Reinikainen et al., which compared oxcarba-
zepine with carbamazepine, the two tablets that were offered were de-
scribed as identical.22
Outcome results
Oxcarbazepine versus placebo
50% reduction in seizure frequency (Figure 2)
Two studies analyzed the outcome “60% reduction in seizure fre-
quency”. The study by Barcs included adult patients, while the study by 
Glauser only included children. Both among the adults and among the 
children, oxcarbazepine was shown to be statistically more effective than 
placebo, independent of the dose. An increase in the effect could be seen 
with increasing dosage.20,21 Among the adult patients, the response rate 
after using oxcarbazepine at a dose of 600 mg was 27% (45/168) (risk 
relative, RR 2.11; 95% confidence interval, CI 1.32 to 3.35; number 
needed to treat, NNT = 7); at a dose of 1,200 mg, it was 41% (73/177) 
(RR 3.24; 95% CI 2.11 to 4.98; NNT = 4); and at a dose of 2,400 mg, 
it was 50% (87/174) (RR 3.83; 95% CI 2.59 to 5.97; NNT = 3); while 
in the placebo group, the response rate was 13% (22/173). Among the 
children, the response rate in the group using oxcarbazepine was 41% 
(57/138), while in the placebo group it was 22% (28/129) (RR 2.11; 
95% CI 1.32 to 3.35; NNT = 5). 
Patients without seizures during the follow-up period (Figure 3)
It was possible to perform a meta-analysis on the comparison be-
tween oxcarbazepine 2,400 mg and placebo, from the studies by 
Schachter et al.19 and Barcs et al.20 At this dose, the rate of patients 
who were seizure-free with the use of oxcarbazepine was 23% (51/225), 
while in the placebo group, the rate was 1% (2/224). This difference 
was statistically significant (RR 25.41; 95% CI 6.26 to 103.10) and re-
sulted in a risk difference of 22% and an NNT of 5, thus signifying that 
it would be necessary to treat five patients with oxcarbazepine for there 
to be one seizure-free patient. This meta-analysis did not show hetero-
geneity. 
At the dosages of 600 mg and 1,200 mg, only the study by Barcs et 
al. was included.20 Oxcarbazepine at a dose of 600 mg was not shown 
to be more effective than placebo (RR 5.15; 95% CI 0.61 to 43.61), 
whereas at the dosage of 1,200 mg, a statistically significant benefit was 
observed. The response rate after using the drug was 10% (18/177), 
compared with 1% among the patients who received placebo (RR 
17.59; 95% CI 2.37 to 130.35). 
Among children, oxcarbazepine was not statistically different from 
placebo when the outcome was to put a complete end to the crises (RR 
4.67; 95% CI 0.55 to 39.47).
Dropout due to adverse events (Figure 4)
The studies by Barcs et al.20 and Glauser et al.21 were included. No 
meta-analysis was performed. Among the adult patients, the dose of 600 
mg did not present any increase in the risk of dropout due to adverse 
events (RR 1.37; 95% CI 0.73 to 2.59), but at the doses of 1,200 mg 
and 2,400 mg, the dropout rates were respectively 36% (64/177) and 
67% (116/174) and were statistically significant in relation to placebo, 
which had a rate of 9% (15/173). 
Among children using oxcarbazepine, the dropout rate due to ad-
verse events was 10% (14/138), while among those using placebo, it was 
3% (4/129). This difference was statistically significant (RR 3.27; 95% 
CI 1.11 to 9.68).
Incidence of adverse events (Figure 5)
It was possible to perform meta-analysis in relation to the dose 
of 2,400 mg because two studies (Schachter et al.19 and Barcs et 
al.20) could be grouped. At this dosage, the rate of adverse events 
among patients receiving oxcarbazepine was 91% (208/228), com-
pared with 72% in the placebo group. This difference was statisti-
cally significant (RR 1.27; 95% CI 1.16 to 1.39).19,20 Five patients 
needed to be treated with oxcarbazepine for there to be one adverse 
event more than with placebo.
At the dose of 600 mg, no statistically significant difference in the 
risk that adverse events would occur was observed (RR 1.1; 95% CI 
0.99 to 1.22). With the use of oxcarbazepine at the dose of 1,200 mg, 
an increase in the rate of adverse events in relation to placebo was ob-
served (90% versus 76%). This difference was statistically significant 
Oxcarbazepine Placebo Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.1.1 Oxcarbazepine 600 mg versus placebo
Barcs et al.20 45 168 22 173 2.11 [1.32, 3.35]
1.1.2 Oxcarbazepine 1,200 mg versus placebo
Barcs et al.20 73 177 22 173 3.24 [2.11, 4.98]
1.1.3 Oxcarbazepine 2,400 mg versus placebo
Barcs et al.20 87 174 22 173 3.93 [2.59, 5.97]
1.1.4 Oxcarbazepine in children 30-46 mg/kg/day
Glauser et al.21 57 138 28 129 1.90 [1.30, 2.79]
0.02 0.1 1 10 50
Favors placebo Favors oxcarbazepine
Figure 2. Forest plot showing that oxcarbazepine was more effective than placebo for reducing the frequency of crises by 50%, independent of the dosage 
or whether it was given to adults or children, because the horizontal line representing the confidence interval for each comparison did not cross the vertical 
line representing relative risk of 1.0, at any of the dosages analyzed (ellipses A, B, C and D).
A
B
C
D
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Figure 4. Forest plot showing that the risk of dropping out from the treatment because of adverse events was statistically greater among the adult patients 
who used oxcarbazepine at the dosages of 1,200 mg (ellipse B) and 2,400 mg (ellipse C), and among children (ellipse D), because the horizontal line 
representing the confidence interval for each comparison did not cross the vertical line representing relative risk of 1.0. However, at the dosage of 600 mg 
(ellipse A), the chance of dropping out because of the use of oxcarbazepine was no greater, because the confidence interval included the relative risk of 1.0.
Oxcarbazepine Placebo Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total M-H, Fixed, 95% CI M-H, Fixed. 95% CI
1.5.1 Oxcarbazepine 600 mg versus placebo 
Barcs et al.20 20 168 15 173 1.37 [0.73, 2.59]
1.5.2 Oxcarbazepine 1,200 mg versus placebo 
Barcs et al.20 64 177 15 173 4.17 [2.47, 7.03] 
1.5.3 Oxcarbazepine 2,400 mg versus placebo
Barcs et al.20 116 174 15 173 7.69 [4.69, 12.61] 
1.5.4 Oxcarbazepine in children 30-46 mg/kg/day
Glauser et al.21 14 138 4 129 3.27 [1.11, 9.68]
0.01 0.1 1 10 100
Favors oxcarbazepine Favors placebo
A
B
C
D
Figure 3. Forest plot showing that oxcarbazepine was more effective than placebo with regard to leaving the patients free from crises, for adult patients at 
the dosages of 1,200 mg (ellipse B) and 2,400 mg (ellipse C), because the horizontal line representing the confidence interval for each comparison did 
not cross the vertical line representing relative risk of 1.0. At the dosage of 600 mg (ellipse A) and among children (ellipse D), oxcarbazepine was no more 
effective than placebo because the confidence interval included the relative risk of 1.0.
Oxcarbazepine Placebo Risk Ratio Risk Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI 
1.2.1 Oxcarbazepine 600 mg versus placebo
Barcs et al.20 5 168 1 173 19.6% 5.15 [0.61, 43.611] 
Subtotal (95% CI) 168 173 19.6% 5.15 [0.61, 43.61] 
Total events 5 1
Heterogeneity: Not applicable 
Test for overall effect: Z = 1.50 (P = 0.13) 
1.2.2 Oxcarbazepine 1,200 mg versus placebo 
Barcs et al.20 18 177 1 173 20.1% 17.59 [2.37, 130.35] 
Subtotal (95% CI) 177 173 20.1% 17.59 [2.37,130.35]
Total events 18 1
Heterogeneity: Not applicable 
Test for overall effect: Z = 2.81 (P = 0.005) 
1.2.3 Oxcarbazepine 2,400 mg versus placebo 
Barcs et al.20 38 174 1 173 19.9% 37.78 [5.25, 272.12] 
Schachter et al.19 13 51 1 51 19.9% 13.00 [1.77, 95.73] 
Subtotal (95% CI) 225  224 39.8% 25.41 [6.26,103.10]
Total events 51 2 
Heterogeneity: Chi2= 0.59, df= 1 (P = 0.44); 12= 0% 
Test for overall effect: Z = 4.53 (P < 0.00001) 
1.2.4 Oxcarbazepine in children 30-46 mg/kg/day
Glauser et al.21 5 138 1 129 20.5% 4.67 [0.55, 39.47]
Subtotal (95% CI) 138 129 20.5% 4.67 [0.55, 39.47]
Total events 5 1
Heterogeneity: Not applicable
Test for overall effect: Z= 1.42 (P = 0.16)
Total (95% CI) 708 699 100.0% 15.61 [6.37,38.26]
Total events 79 5
Heterogeneity: Chi2= 3.08, df= 4 (P = 0.54); 12= 0%
Test for overall effect: Z = 6.01 (P < 0.00001)
Test for subgroup differences: Not applicable
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(RR 1.18; 95% CI 1.08 to 1.30). Thus, for every seven patients treated, 
there would be one adverse event more than with placebo.
Among children, no statistically significant difference in the risk of 
adverse events was observed (RR 1.04; 95% CI 0.87 to 1.24).
Incidence of adverse events classified as serious (Figure 6)
Only the study by Barcs et al. evaluated this outcome.20 There was 
no statistically significant difference in the risk that adverse events clas-
sified as serious would occur, at the doses of 600 mg (RR 1.37; 95% CI 
0.59 to 3.17), 1,200 mg (RR 0.98; 95% CI 0.40 to 2.40) or 2,400 mg 
(RR 1.99; 95% CI 0.92 to 4.30). 
Oxcarbazepine versus carbamazepine
Only one study comparing these two interventions was identified. 
No statistically significant differences in the following outcomes were 
observed: worsening of seizures (RR 0.56; 95% CI 0.06 to 5.63; Fig-
ure 7), seizure frequency (weighted mean difference, WMD 0.10; 95% 
CI -1.43 to 1.63; Figure 8) or incidence of adverse events (RR 0.96; 
95% CI 0.37 to 1.39; Figure 9).
DISCUSSION
After an exhaustive search in several databases with the aim of prov-
ing whether oxcarbazepine was effective and safe for treating refractory 
epilepsy, we only identified four randomized clinical trials. Three clini-
cal trials compared oxcarbazepine with placebo and one other clinical 
trial compared oxcarbazepine with carbamazepine. No other clinical tri-
als comparing oxcarbazepine with other antiepileptic drugs were identi-
fied. Meta-analyses could only be performed in relation to certain vari-
ables for the comparison between oxcarbazepine at the dose of 2,400 
mg and placebo.
Among adults, it can be affirmed that oxcarbazepine is effective for 
treating refractory epilepsy, with regard to obtaining a 50% reduction 
in the frequency of crises. The best results were obtained at the dosages 
of 1,200 mg and 2,400 mg, since at these dosages, the patients’ chances 
of remaining free from crises were greater than at the dose of 600 mg. 
This response profile demonstrates that there is a dose-response gradi-
ent, with greater efficacy as the dose is increased. However, the dosage 
of 2,400 mg presented lower tolerance, thus resulting in a much high-
Figure 5. Forest plot showing that the risk of adverse events was statistically greater among the adult patients who used oxcarbazepine at the dosages of 
1,200 mg (ellipse B) and 2,400 mg (ellipse C), because the horizontal line representing the confidence interval for each comparison did not cross the 
vertical line representing relative risk of 1.0. Thus, the chances of presenting adverse events after dosages of 1,200 mg and 2,400 mg were respectively 
1.18 and 1.27 times greater than what was observed among the patients who used placebo. However, among the adults who used the dosage of 600 mg 
(ellipse A) and among the children (ellipse D), the chance that adverse events might occur because of the use of oxcarbazepine was no greater, because 
the confidence interval included the relative risk of 1.0.
Oxcarbazepine Placebo Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI M-H, Fixed, 95% CI
1.6.1 Oxcarbazepine 600 mg versus placebo
Barcs et al.20 141 168 132 113 100.0% 1.10 [0.99,122]
Subtotal (95% CI) 168 173 100.0% 1.10 [0.99,122]
Totale events 141 132 
Heterogeneity: Not applicable
Test for overall effect Z= 1.76 (P=008)
1.6.2 Oxcarbazepine 1,200 mg versus placebo
Barcs et al.20 160 177 132 173 100.0% 1.18 [1.08, 1.30]
SubtotaI (95% CI) 177 173 100.0% 1.18 [1.08, 1.30]
Tolal events 160 132 
Heterogeneity: Not applicable
Test for overall effect Z= 3.46 (P=0.0005)
1.6.3 Oxacarbazepine 2.400 mg versus pIacebo
Barcs et al.20 170 177 132 173 82.2% 
Schachter et al.19 38 51 29 51 17.8%
Subtotal (95% CI) 228 224 100.0%
Total events 208 161 
Heterogeneity: Chi2= 0.08, df= 1 (P=0.78), I2= 0%
Test for overall effect Z= 5.22 (P< 0.00001)
1.6.4 Oxcarbazepine em crianças 30-46 mg/kg/day
Glauser et al.21 91 138 82 129 100.0% 1.04 [0.87, 1.24]
Subtotal (95% CI) 138 129 100.0% 1.04 [0.87, 1.24]
Tolal events 91 82 
Heterogeneity: Not applicable
Test for overall effect: Z= 0.41 (P= 0.69)
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er dropout rate due to adverse events, such that 67% of the patients 
using this dose dropped out of the treatment because of adverse reac-
tions, compared with a dropout rate of 36% among those who received 
1,200 mg.
With regard to the outcome of putting a complete end to the cri-
ses, even under conditions in which oxcarbazepine was more effective 
than placebo, the rate of patients without crises was very small, although 
greater than what was observed with placebo (1%). For example, at the 
dose of 1,200 mg, only 10% presented this response in a study with 
only 28 days of follow-up. At a dose of 2,400 mg, two studies with fol-
low-ups of 10 and 28 days could be grouped in a meta-analysis, which 
showed that only 23% of the patients remained free from seizures.
Only one randomized study on children was identified.21 This used 
dosages of 30 to 46 mg/kg and it only showed a benefit in relation to 
reducing the seizure frequency by 50%. Use of the drug was not asso-
ciated with an increase in the rate of seizure-free patients.21 Regarding 
safety, we observed a greater dropout rate due to adverse events, with 
drug use in relation to placebo.
Although non-randomized studies have shown that oxcarbazepine 
is better tolerated, in terms of presenting fewer adverse events than seen 
with carbamazepine and phenytoin, we were unable to confirm this in-
formation through studies with greater scientific robustness. Only one 
study comparing oxcarbazepine with carbamazepine was included, with 
a very small sample and dubious methodological quality. From this, no 
Oxcarbazepine Carbamazepine Mean Difference Mean Difference
Study or Subgroup Events Total Events Total IV, Fixed, 95% CI IV, Fixed, 95% CI
Reinikainen et al.22 7 16 11 18 0.72 [0.37, 1.39]
0.01 0.1 1 10 100
Favors oxcarbazepine Favors carbamazepine
Figure 9. Forest plot showing that the risk of adverse events was not statistically different between oxcarbazepine and carbamazepine, because the 
confidence interval included the relative risk of 1.0.
Oxcarbazepine Carbamazepine Mean Difference Mean Difference
Study or Subgroup Mean SD Total Mean SD Total IV, Fixed, 95% CI IV, Fixed, 95% CI
Reinikainen et al.22 1.6 2.4 16 1.52 2.12 18 O.10 [-1.43, 1.63] 
-4 -2 0 2 4
Favors oxcarbazepine Favors carbamazepine
Figure 8. Forest plot showing that the frequency of crises was not statistically different between oxcarbazepine and carbamazepine, because the 
confidence interval included the relative risk of zero.
Figure 6. Forest plot showing that the risk of adverse events classified as serious occurring through the use of oxcarbazepine, among adult patients, was 
not statistically greater than through the use of placebo, independent of the dosage, because the confidence interval included the relative risk of 1.0. The 
study by Glauser et al.,21 which evaluated the effect of oxcarbazepine among children, did not evaluate this outcome.
Oxcarbazepine Placebo Risk Ratio Risk Ratio
Study or Subgroup Events Total Events Total M-H, Fixed 95% CI M-H, Fixed, 95% CI
2.7.1 Oxcarbazepine 600 mg versus placebo
Barcs et al.20 12 168 9 173 1.37 [0.59,317]
2.7.2 Oxcarbazepine 1,200 mg versus placebo
Barcs et al.20 9 177 9 173 098 [0.40.140]
2.7.3 Oxcarbazepine 2,400 mg versus placebo
Barcs et al.20 18 174 9 173 199 [0 92, .4.30]
0.05 0.2 1          5 20
Favors oxacarbazepine Favors placebo
Figure 7. Forest plot showing that the risk that crises might worsen was not statistically different between oxcarbazepine and carbamazepine, because the 
confidence interval included the relative risk of 1.0.
Oxcarbazepine Carbamazepine Risk Ratio Risk Ratio
Study or Subgroup Events TotaI Events TotaI M-H, Fixed, 95% CI M-H, Fixed, 95% CI
Reinikainen et al.22 1 16 2 18 056 [0.06, 5.63]
001 0.1 1 10 100 
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difference in efficacy and safety between these two drugs could be iden-
tified in relation to patients with refractory epilepsy.
One limitation in interpreting the results from this systematic re-
view came from the lack of standardization of the therapeutic response 
between the studies, which made it difficult to perform meta-analyses. 
Another important limitation was the very short follow-up in some 
studies. In one study, the efficacy was evaluated only ten days after the 
treatment (Schachter et al.). The study with the longest follow-up was 
the one by Glauser et al., in which the response to treatment was evalu-
ated after 112 days, i.e. just over three months.19,21 
Ethical problems strongly influence the planning of clinical trials 
involving epileptic patients. It is unthinkable to leave patients with re-
fractory epilepsy using placebo for long periods. On the other hand, it 
needs to be asked whether the patients who remained free from seizures 
over periods of 10, 28 or 112 days following their treatment, as seen in 
the studies included in this systematic review, would have remained free 
from seizures over periods of six or twelve months or even longer. The 
answer to this question has to be that it is unlikely and, for this reason, a 
minimum follow-up period of six months for evaluating the therapeutic 
response of antiepileptic drugs is recommended.23-25 
Another matter to be considered in clinical trials is the type of out-
come that would best reflect the efficacy of treatments with antiepilep-
tic drugs. The best way of measuring the effect of such medications is 
through the rate of seizure-free patients because this outcome is not 
only unequivocal but also associated with better quality of life,23,26,27 in 
comparison with patients with a 50% reduction in seizure frequency. 
Nonetheless, it must always be taken into account that, for ethical rea-
sons, it is necessary to make comparisons with other active treatments, 
which could consist of other drugs or treatments involving a controlled 
diet, for example.
CONCLUSIONS
Implications for practice
• There is moderate evidence indicating that oxcarbazepine is an ef-
fective alternative treatment for cases of partial or generalized epi-
lepsy among children or adults that had been refractory to previous 
treatments with antiepileptic drugs. 
• The evidence is insufficient to affirm whether oxcarbazepine is safe.
• No evidence regarding any effect from oxcarbazepine on cognition 
could be obtained.
• There is insufficient evidence to affirm that oxcarbazepine is equal 
or superior to carbamazepine for treating refractory epilepsy.
Implications for research
• New randomized clinical trials evaluating the efficacy and safety of 
oxcarbazepine among adults and children with refractory epilepsy 
are needed. These new studies should have adequate randomization 
methods, samples with sufficient numbers of participants and fol-
low-up periods of at least six months.
• Because of the small number of randomized clinical trials, a system-
atic review of observational studies is needed in order to evaluate the 
safety and cognitive effects of oxcarbazepine.
• Randomized clinical trials as described in the preceding paragraph, 
comparing oxcarbazepine with other antiepileptic drugs and with 
other types of clinical treatment, for treating refractory epilepsy, are 
needed.
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